- Home
- ODV vs TVRD Comparison
ODV vs TVRD Comparison
Compare ODV & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODV
- TVRD
- Stock Information
- Founded
- ODV 2005
- TVRD 2017
- Country
- ODV Canada
- TVRD United States
- Employees
- ODV N/A
- TVRD N/A
- Industry
- ODV Precious Metals
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- ODV Basic Materials
- TVRD Health Care
- Exchange
- ODV Nasdaq
- TVRD Nasdaq
- Market Cap
- ODV 270.6M
- TVRD 246.5M
- IPO Year
- ODV N/A
- TVRD N/A
- Fundamental
- Price
- ODV $2.05
- TVRD $25.77
- Analyst Decision
- ODV
- TVRD Strong Buy
- Analyst Count
- ODV 0
- TVRD 3
- Target Price
- ODV N/A
- TVRD $60.67
- AVG Volume (30 Days)
- ODV 454.6K
- TVRD 56.7K
- Earning Date
- ODV 08-11-2025
- TVRD 05-13-2025
- Dividend Yield
- ODV N/A
- TVRD N/A
- EPS Growth
- ODV N/A
- TVRD N/A
- EPS
- ODV N/A
- TVRD N/A
- Revenue
- ODV $1,943,159.00
- TVRD N/A
- Revenue This Year
- ODV $539.98
- TVRD N/A
- Revenue Next Year
- ODV $397.65
- TVRD N/A
- P/E Ratio
- ODV N/A
- TVRD N/A
- Revenue Growth
- ODV N/A
- TVRD N/A
- 52 Week Low
- ODV $1.16
- TVRD $8.13
- 52 Week High
- ODV $2.75
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- ODV 52.33
- TVRD N/A
- Support Level
- ODV $1.95
- TVRD N/A
- Resistance Level
- ODV $2.29
- TVRD N/A
- Average True Range (ATR)
- ODV 0.12
- TVRD 0.00
- MACD
- ODV -0.01
- TVRD 0.00
- Stochastic Oscillator
- ODV 30.84
- TVRD 0.00
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.